peptidylprolyl isomerase A pseudogene 37Genealiases: []
Q-omics provides the consensus-scored PPIAP37 profile across patient tissues and cancer cell-line models. PPIAP37 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, PPIAP37 is differentially expressed in 4, with the highest sampling consensus in PAAD. Additionally, PPIAP37 RNA expression shows 6,168 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight MESO, PAAD, and STAD as cancer lineages where PPIAP37 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPIAP37 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPIAP37 survival associations across molecular data types. PPIAP37 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPIAP37 RNA expression–survival associations across cancer types. High PPIAP37 expression shows unfavorable associations in MESO, KICH, STAD, OV and UCEC, but favorable associations in SKCM. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for PPIAP37 RNA expression.
This table summarizes PPIAP37 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in PAAD for RNA.
This table ranks reproducible tumor–normal expression differences for PPIAP37. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPIAP37 shows lower tumor expression in PAAD and higher tumor expression in PRAD, STAD and HNSC. The PAAD box plot shows higher PPIAP37 RNA expression in normal versus tumor tissue (log2 FC = −0.190, t-test p = .010).
This table shows molecular features associated with PPIAP37 in patient tissues and cancer cell lines. In patient samples, PPIAP37 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
